Skip to main content

Advertisement

Table 1 Subject baseline demographics and characteristics

From: Post-marketing surveillance data of thrombomodulin alfa: sub-analysis in patients with sepsis-induced disseminated intravascular coagulation

Item   Subjects (n) Rate (%)
Sex Male 1038 58.1
  Female 749 41.9
Age (years) 0–14 86 4.8
  15–64 559 31.3
  65–74 491 27.5
  75–84 498 27.9
  ≥ 85 149 8.3
  Unknown 4 0.2
Source of sepsis Lungs 346 19.4
  Abdomen 396 22.2
  Urine 180 10.1
  Skin 48 2.7
  Focus-unknown 533 29.8
  Others 284 15.9
DIC score (JAAM criteria) 4 216 15.4
  5 368 26.3
  6 325 23.2
  7 191 13.6
  8 300 21.4
SOFA score 0–7 266 24.4
  8–10 270 24.8
  11–13 275 25.3
  ≥ 14 278 25.5
SIRS score 2 394 24.4
  3 708 43.8
  4 513 31.8
Other anticoagulant treatment for DIC (Overall/after TM-α administration) 1,320/1,020 73.9/57.1
AT concentrate 876/476 49.0/26.6
Synthetic protease inhibitors 816/333 45.7/18.6
Heparin derivatives 427/212 23.9/11.9
Duration (days) of DIC before TM-α administration 0 1,134 63.5
  1 345 19.3
  2 110 6.2
  3 59 3.3
  4–6 78 4.4
  ≥ 7 61 3.4
  1. AT antithrombin, DIC disseminated intravascular coagulation, JAAM Japanese Association for Acute Medicine, SIRS systemic inflammatory response syndrome, SOFA Sequential Organ Failure Assessment, TM-α thrombomodulin alfa.